# Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers

> **NCT00236301** · PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 99 (actual)

## Conditions studied

- Healthy Symptomatic Menopausal Women

## Interventions

- **DRUG:** CLIMASTON (drug)
- **DRUG:** 17 Beta-estradiol (2mg/day)and (1mg/day)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00236301
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2006-06
- **Final completion:** 2007-01
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** terminated
- **Last updated:** 2008-01-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236301, "Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00236301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*